581 related articles for article (PubMed ID: 19508669)
1. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients.
Diedrich B; Ringdén O; Watz E; Shanwell A
Vox Sang; 2009 Oct; 97(3):254-9. PubMed ID: 19508669
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo effects of potassium and magnesium on storage up to 7 days of apheresis platelet concentrates in platelet additive solution.
Diedrich B; Sandgren P; Jansson B; Gulliksson H; Svensson L; Shanwell A
Vox Sang; 2008 Feb; 94(2):96-102. PubMed ID: 18034788
[TBL] [Abstract][Full Text] [Related]
3. Patient and product factors affecting platelet transfusion results.
Heim D; Passweg J; Gregor M; Buser A; Theocharides A; Arber C; Meyer-Monard S; Halter J; Tichelli A; Gratwohl A
Transfusion; 2008 Apr; 48(4):681-7. PubMed ID: 18208413
[TBL] [Abstract][Full Text] [Related]
4. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy.
Akkök CA; Brinch L; Lauritzsen GF; Solheim BG; Kjeldsen-Kragh J
Vox Sang; 2007 Jul; 93(1):42-8. PubMed ID: 17547564
[TBL] [Abstract][Full Text] [Related]
5. Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days.
Shanwell A; Diedrich B; Falker C; Jansson B; Sandgren P; Sundkvist L; Svensson L; Vesterinen M; Gulliksson H
Transfusion; 2006 Jun; 46(6):973-9. PubMed ID: 16734814
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.
Gurkan E; Patah PA; Saliba RM; Ramos CA; Anderson BS; Champlin R; de Lima M; Lichtiger B
Bone Marrow Transplant; 2007 Sep; 40(5):461-4. PubMed ID: 17589530
[TBL] [Abstract][Full Text] [Related]
7. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
[TBL] [Abstract][Full Text] [Related]
8. Autologous platelet transfusion in patients receiving high-dose chemotherapy and circulating progenitor cell transplantation for stage II/III breast cancer.
Pedrazzoli P; Perotti C; Noris P; Da Prada GA; Zibera C; Battaglia M; Gibelli N; Preti P; Pavesi L; Torretta L; Balduini CL; Salvaneschi L; Robustelli della Cuna G
Haematologica; 1998 Aug; 83(8):718-23. PubMed ID: 9793256
[TBL] [Abstract][Full Text] [Related]
9. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
[TBL] [Abstract][Full Text] [Related]
10. Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial.
Heddle NM; Cook RJ; Blajchman MA; Barty RL; Sigouin CS; Boye DM; Nelson EJ; Kelton JG
Transfusion; 2005 Jun; 45(6):896-903. PubMed ID: 15934987
[TBL] [Abstract][Full Text] [Related]
11. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study.
Simonsen AC; Johansson PI; Conlan MG; Jacquet M; Lin JS; Junge K; Lin L; Sørensen H; Borregaard N; Flament J
Transfusion; 2006 Mar; 46(3):424-33. PubMed ID: 16533286
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis.
Eriksson L; Kristensen J; Olsson K; Bring J; Högman CF
Vox Sang; 1996; 70(2):69-75. PubMed ID: 8801766
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients.
Diedrich B; Remberger M; Shanwell A; Svahn BM; Ringdén O
Transfusion; 2005 Jul; 45(7):1064-72. PubMed ID: 15987349
[TBL] [Abstract][Full Text] [Related]
14. Storage of buffy-coat-derived platelets in additive solutions: in vitro effects on platelets stored in reformulated PAS supplied by a 20% plasma carry-over.
Sandgren P; Mayaudon V; Payrat JM; Sjödin A; Gulliksson H
Vox Sang; 2010 Apr; 98(3 Pt 2):415-22. PubMed ID: 19788514
[TBL] [Abstract][Full Text] [Related]
15. In vitro function of buffy coat-derived platelet concentrates stored for 9 days in CompoSol, PASII or 100% plasma in three different storage bags.
Cardigan R; Sutherland J; Garwood M; Bashir S; Turner C; Smith K; Hancock V; Wiltshire M; Pergande C; Williamson LM
Vox Sang; 2008 Feb; 94(2):103-12. PubMed ID: 18034786
[TBL] [Abstract][Full Text] [Related]
16. Storage of buffy-coat-derived platelets in additive solutions at 4 degrees C and 22 degrees C: flow cytometry analysis of platelet glycoprotein expression.
Sandgren P; Hansson M; Gulliksson H; Shanwell A
Vox Sang; 2007 Jul; 93(1):27-36. PubMed ID: 17547562
[TBL] [Abstract][Full Text] [Related]
17. Effects of platelet concentrate storage time reduction in patients after blood stem cell transplantation.
Heuft HG; Goudeva L; Krauter J; Peest D; Buchholz S; Tiede A
Vox Sang; 2013 Jul; 105(1):18-27. PubMed ID: 23521355
[TBL] [Abstract][Full Text] [Related]
18. Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation.
Briggs C; Hart D; Kunka S; Oguni S; Machin SJ
Transfus Med; 2006 Apr; 16(2):101-9. PubMed ID: 16623916
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of apheresis platelets stored for 5 days in 65% platelet additive solution/35% plasma.
Vassallo RR; Adamson JW; Gottschall JL; Snyder EL; Lee W; Houghton J; Elfath MD
Transfusion; 2010 Nov; 50(11):2376-85. PubMed ID: 20497516
[TBL] [Abstract][Full Text] [Related]
20. Secondary failure of platelet recovery after hematopoietic stem cell transplantation.
Bruno B; Gooley T; Sullivan KM; Davis C; Bensinger WI; Storb R; Nash RA
Biol Blood Marrow Transplant; 2001; 7(3):154-62. PubMed ID: 11302549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
